EP1231886A1 - Composition topique pour la peau - Google Patents

Composition topique pour la peau

Info

Publication number
EP1231886A1
EP1231886A1 EP00980601A EP00980601A EP1231886A1 EP 1231886 A1 EP1231886 A1 EP 1231886A1 EP 00980601 A EP00980601 A EP 00980601A EP 00980601 A EP00980601 A EP 00980601A EP 1231886 A1 EP1231886 A1 EP 1231886A1
Authority
EP
European Patent Office
Prior art keywords
component
skin composition
acid
skin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00980601A
Other languages
German (de)
English (en)
Other versions
EP1231886A4 (fr
Inventor
James R. Mayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Access Business Group International LLC
Original Assignee
Alticor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alticor Inc filed Critical Alticor Inc
Publication of EP1231886A1 publication Critical patent/EP1231886A1/fr
Publication of EP1231886A4 publication Critical patent/EP1231886A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Definitions

  • ROS reactive oxygen species
  • OOS oxidizing species
  • the ROS species include superoxide (O 2 ⁇ ), hydrogen peroxide (H 2 O 2 ), peroxy radicals (HO 2 and RO 2 ) alkyl peroxide (R 2 O 2 ), hydroxyl radical ( OH), alkoxy radical ( OR), and singlet oxygen.
  • the OOS species include hypohalous acids (HOX) (where X is chloride, bromide, iodide), Z-amines (where Z is either chlorinated or ammoniated amine containing compounds, nitric oxide (NO), ammonia, cyclooxygenase, phospholipase A 2 , phospholipase C and transition metals.
  • the present invention is directed to a complex containing an effective amount of selected components to provide a defense against the various pathway mechanisms of ROS.
  • the invention also contemplates a method for the treatment of the skin.
  • the composition and method of this invention are directed to the prevention of the adverse or detrimental effects of ROS.
  • the present invention also contemplates a composition that repairs damage caused by the ROS.
  • the complex composition contains at least one anti- superoxide component, at least one anti-hydrogen peroxide component, at least one anti-hydroxyl radical component, and optionally at least one chain breaker component.
  • the composition also contains a component that aids in cellular energy product, a component that aids in collagen synthesis, and a component that aids or provides cellular activity.
  • FIG. 1 is a graph showing the increase in erythema 30 minutes after UV exposure on human skin to which formulations according to the present invention were applied.
  • FIG. 2 is a graph showing the increase in erythema 10 hours after UV exposure on human skin to which formulations according to the present invention were applied
  • the present invention provides a topical skin complex composition that provides a defense mechanism against a variety of ROS.
  • the complex composition contains at least one anti- superoxide component, at least one anti-hydrogen peroxide component, at least one anti-hydroxyl radical component, and optionally at least one chain breaker.
  • the composition also contains a component that aids in cellular energy product, a component that aids in collagen synthesis, and a component that aids or provides cellular activity.
  • the composition also includes a cosmetically or pharmaceutically acceptable carrier.
  • a cosmetically or pharmaceutically acceptable carrier When a carrier is present, the complex forms from about 0.01% to about 10% by weight of the total composition, preferably from about 1% to about 7% of the total composition.
  • this component includes those materials having anti- superoxide activity and, in particular, those having superoxide dismutase activity.
  • it includes those components that can catalyze a dismutation reaction.
  • it includes superoxide dismutase (SOD), SODs modified by grafting polyalkylene oxide, polyethylene glycol, polysaccharide or acylated groups, salts of SOD, substances containing such SOD products, porphorins and materials with superoxide dismutase-like activity.
  • SOD superoxide dismutase
  • SODs superoxide dismutase
  • they may be animal (bovine, porcine, and the like), human (blood), or plant (fungi, algae, spinach, and the like). They may also be obtained from bacteria or yeast, or alternatively by a biotechnological route.
  • SODs that may have application in the present invention are described in U.S. Pat. No. 5,526,507, the contents of which is incorporated herein by reference.
  • the SOD forms from about 0.01% to about 5% by weight of the complex.
  • the SOD is included in the complex in an amount from about 0.1 % to about 2% by weight.
  • this component is a thiol or thiol derivative.
  • thiol is to be understood to be an organic compound characterized by the -SH group.
  • Thiol derivatives are organic compounds that are either derivatives that retain the -SH group or are thio ethers or thio esters, in which case the -SH group is converted into the -SR group.
  • Suitable thiol and thiol derivatives may include captopril, cysteamine, ergothioneine, mercaptopropionylglycine, penicillamine, N-acetylcysteine, S- acetylcysteine, N,S-diacetylcysteine, N,S-diacetylcysteinamide, cysteine ethyl ester, N-acetylcrysteine ethyl ester, S-acetylcysteine ethyl ester, N,S- diacetylcysteine ethyl ester, thioglycolic acid, cysteine, homocysteine, glutathione, thioglycerol, thiomalic acid, 2-mercaptopropionic acid, 3- mercaptopropionic acid, thiodiglycol, 2-mercaptoethanol, dithioreitol, thioxanthen
  • the cosmetically acceptable salts include, but are not limited to alkali metal salts, e.g., sodium, lithium, potassium, and rubidium salts; alkaline earth metal salts, e.g. magnesium, calcium, and strontium salts; non-toxic heavy metal salts, e.g., aluminum and zinc salts; boron salts; silicon salts; ammonium salts; trialkylammonium salts, e.g. trimethylammonium and triethylammonium, and tetraalkylonium salts.
  • the anti-hydrogen peroxide component is incorporated into the complex in an amount from about 0.001% to about 5% by weight, preferably from about 0.01% to about 2.5%, more preferably from about 0.1 % to about 1% by weight of the complex.
  • the anti-hydroxyl radical component can include one or more of the following: tocopherol, tocopherol derivatives, tetrahydrodiferuloylmethane, grape seed extract, green tea extract, turmeric acid, curcuminoids, tetrahydrocurcuminoids catechins, epigallocatechin 3-0-gallate and polyphenols, oligomeric proanthocyanidins, bioflavonoids, flavonoids, and mixtures thereof.
  • Tocopherol (Vitamin E) and its derivatives such as esters of tocopherol are useful in the composition of the present invention.
  • Suitable tocopherols include the monomethyl, dimethyl, or triethyl derivatives of tocol, including but not limited to, alpha tocopherol, beta tocopherol, gamma tocopherol, delta tocopherol, epsilon tocopherol, zeta tocopherol, and eta tocopherol.
  • Suitable esters of tocopherol include but are not limited to tocopheryl acetate, tocopheryl succinate, tocopheryl benzoate, tocopheryl propionate, tocopheryl sorbate, tocopheryl oleate, tocopheryl orotate, tocopheryl linoleate, tocopheryl nicotinate, and the 2-ethyl-hexanoate ester.
  • the tocopherol or its derivatives are included in the complex of the present invention, they are used at level from about 10% to about 98%.
  • Tetrahydrodiferuloylmethane and/or turmeric extract may also be incorporated into the complex at levels from about 0.1 % to about 20% by weight of the complex, preferably from about 1% to about 10% by weight.
  • Grape seed extract and complexes of grape seed extract with phospholipids may also be beneficial for use in the present invention.
  • the extracts from grape seed include a mixture polyphenols such as epicatechin, proanthocyanidins, and catechins.
  • a suitable complex of grape seed extract and phospholipid is described in U.S. Pat. No. 4,963,527, the contents of which is incorporated herein by reference.
  • the grape seed extract or its complex with phospholipids is present in an amount from about 0.001% to about 5% by weight of the complex, preferably from about 0.01% to about 2.5% by weight.
  • Green tea extract may be included in the same amounts as the grape seed extract.
  • Flavonoids and bioflavonoids may also be useful in the present invention. It has been reported in Bravo, Polyphenols: Chemistry, Dietary Sources, Metabolism, and Nutritional Significance, Nutrition Reviews, Vol. 56, No. 11 , 317-33 (November, 1998), the contents of which are incorporated herein by reference, that flavonoids may be subdivided into 13 classes shown below:
  • Flavonoids have, in general, the common structure of diphenyipropanes (C 6 -C 3 -C 6 ) and consist of two aromatic rings linked through three carbons that usually form an oxygenated heterocycle.
  • the basic structure is shown below:
  • Flavonoids occasionally occur in plants as aglycones, although they are most commonly found as glycoside derivatives.
  • the flavonoids may be derived from any suitable source.
  • a preferred source is from citrus.
  • flavonoids When flavonoids are incorporated into the complex, they are present at a level from about 0.001% to about 20% by weight of the complex, preferably from about 0.01% to about 10% by weight.
  • palmitoyl hydroxypropyltrimonium amylopectin can be mixed with camellia sinensis extract. This may be present in amounts ranging from about 0.001% to about 2% by weight of the complex.
  • the chain breaker may include the same components as those described above for the anti-hydroxyl radical component.
  • one or more of the above anti-hydroxyl radical components may also serve as a chain breaker component.
  • Chain breaking antioxidants are those ingredients that can break the chain reaction once lipid peroxidation is initiated.
  • the complex composition may also include components selected to repair the damage caused by the ROS.
  • the compositions of the present invention includes at least one component that provides cellular energy production, at least one component that aids collagen synthesis, and at least one component that aids or provides cellular activity. These components may be used singly or, desirably, in combination.
  • a desirable cellular energy production component includes the ubiquinones.
  • Ubiquinones are widely found in bacteria, fungi, yeasts, plants, and animals. It is known that different species produce isoforms (Q-n) with different numbers of isoprene units (n). For example, the number of isoprene units is 6 (Q 6 ) in some microorganisms, nine (Q 9 ) in plants, and ten (Q 10 ) in humans.
  • Coenzyme Q ⁇ 0 or 2,3,-dimethoxy-5-methyl-6-decaprenyl- benzoquinone functions to recover and maintain respiration and promotes ATP production in terms of energy supply for cellular activities. Derivatives of the ubiquinones such as ubiquinols may also be useful
  • the cellular energy production component for example, coenzyme Q 10
  • coenzyme Q 10 is incorporated into the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
  • hydroxy acids including alpha and beta hydoxy acids may be useful in this regard.
  • the present invention contemplates including one or more alpha or beta hydroxy acids. Suitable examples include lactic, malic, glycolic, citric, and salicylic acid.
  • ascorbic acid Vitamin C
  • ascorbic acid derivative useful in the present invention includes all enantiomers whether singly or in combination.
  • the ascorbic acid is provided in the levo form.
  • the ascorbic acid or its derivatives may be in a water soluble or an oil soluble form.
  • Non-exclusive examples of the vitamin C (ascorbic acid) derivatives are, for instance, the alkyl esters of L-ascorbic acid where the alkyl portion has from 8 to 20 carbon atoms. With respect to the esters, they may be selected from the group consisting of fatty acid mono-, di-, tri- or tetra-esters of ascorbic acid.
  • esters include, but are not limited to ascorbyl palmitate, ascorbyl laureate, ascorbyl myristate, ascorbyl stearate, ascorbyl dipalmitate, ascorbyl dilaurate, ascorbyl dimyristate, ascorbyl distearate, ascorbyl tripalmitate, ascorbyl trilaurate, ascorbyl trimyristate, ascorbyl tristearate, ascorbyl tetrapalmitate (tetrahexyldecyl ascorbate), ascorbyl tetralaurate, ascorbyl tetramyristate, ascorbyl tetrastearateL-ascorbyl palmitate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L-ascorbyl isostearate, L-ascorbyl distearate, L-ascorbyl diisostearate,
  • the salts may be selected from the phosphates and sulfates, preferably phosphate.
  • the ascorbic acid phosphate is generally selected from L-ascorbic acid 3-phosphate, L-ascorbic acid 2-phosphate, L-ascorbic acid 3-pyrophosphate and bis (L-ascorbic acid 3,3-) phosphate.
  • the ascorbic acid phosphate is magnesium or sodium ascorbyl phosphate; more preferably, magnesium ascorbyl phosphate.
  • the ascorbic acid sulfate is generally selected from L-ascorbic acid 3-sulfate, L-ascorbic acid 2-sulfate, L-ascorbic acid 3-pyrosulfate and bis (L-ascorbic acid 3,3-) sulfate.
  • the collagen synthesis component for example, the ascorbic acid and its derivatives, is incorporated in the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
  • retinoids may affect cellular activity and thus it is desirable to incorporate retinoids in the complex of the present invention.
  • the retinoids include retinol, retinal (Vitamin A aldehyde), and retinyl esters such as retinyl acetate, retinyl butyrate, retinyl propionate, retinyl octanoate, retinyl laurate, retinyl palmitate, retinyl oleate, and retinyl linoleate.
  • irritancy mitigants may be incorporated into the compositions to assist in preventing undue discomfort to the user while potentially permitting the dosage level of retinoid to be increased.
  • irritancy mitigants include, but are not limited to ceramides, pseudoceramides, fatty acids, cholesterol, phospholipids, panthenol, oat extract, allantoin, ginkgo biloba, licorice extract, calendula, ginseng, butchers broom, and the like.
  • the cellular activity component for example, the retinoid, is incorporated in the complex at a level ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
  • the complex compositions according to the present invention are generally mixed with a pharmaceutically or cosmetically acceptable vehicle or carrier.
  • the complex compositions of the present invention may be formulated as a solution, gel, lotion, cream, ointment, oil-in-water emulsion, water-in-oil emulsion, or other pharmaceutically or cosmetically acceptable form.
  • the complex compositions of the present invention may also contain various known and conventional cosmetic ingredients so long as they do not detrimentally affect the desired effects.
  • the pharmaceutically acceptable or cosmetically acceptable vehicle acts as a dilutant, dispersant, or carrier for other materials present in the complex composition, so as to facilitate their distribution when the complex composition is applied to the skin.
  • Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners, and powders.
  • the following vehicles can be used alone or as a combination of one or more vehicles.
  • Vehicles may also include propellants such as propane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide; and solvents such as ethyl alcohol, isopropanol, acetone, ethylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, or powders such as chalk, talc, fullers earth, kaolin, starch, gums, collodial silica, sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.
  • propellants such as propane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide
  • solvents such as ethyl alcohol, isopropanol, acetone,
  • Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil,
  • emollients refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
  • suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1 , pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of suitable materials.
  • the composition can optionally comprise suncreens such as inorganic and organic sunscreens to provide protection from the harmful effects of excessive exposure to sunlight during use of the complex composition of the present invention.
  • suncreens such as inorganic and organic sunscreens to provide protection from the harmful effects of excessive exposure to sunlight during use of the complex composition of the present invention.
  • suitable sunscreens include those described in the U.S. OTC Sunscreen Monograph, the contents of which is incorporated herein by reference.
  • composition of the invention can accordingly comprise from 0.1 to 10%, preferably from 1 to 5% by weight of an organic sunscreen material.
  • composition optionally can also comprise as a sunscreen titanium dioxide or zinc oxide having an average particle size of from 1 to 300nm, iron oxide having an average particle size of from 1 to 300nm, silica, such as fumed silica having an average particle size of from 1 to 100nm.
  • a sunscreen titanium dioxide or zinc oxide having an average particle size of from 1 to 300nm iron oxide having an average particle size of from 1 to 300nm
  • silica such as fumed silica having an average particle size of from 1 to 100nm.
  • silica when used as an ingredient in the emulsion according to the invention can provide protection from infrared radiation.
  • Ultrafine titanium dioxide in either of two forms namely water- dispersible titanium dioxide and oil-dispersible titanium dioxide may be used.
  • Water-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which are uncoated or which are coated with a material to impart a hydrophilic surface property to the particles. Examples of such materials include aluminum oxide and aluminum silicate.
  • Oil-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which exhibit a hydrophobic surface property, and which, for this purpose, can be coated with metal soaps such as aluminum stearate, aluminum laurate, or zinc stearate, or with organosilicone compounds.
  • titanium dioxide particles of titanium dioxide having an average particle size of less than 100nm, preferably from 10 to 40nm and most preferably from 15 to 25nm.
  • the total amount of titanium dioxide that can optionally be incorporated in the composition according to the invention is from 1 to 25%, preferably from 2 to 10% and ideally from 3 to 7% by weight of the composition.
  • composition is an emulsion, in which case an oil or oily material (emollient) will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion.
  • an oil or oily material emollient
  • composition can also comprise water, usually up to 95%, preferably from 5 to 95% by weight.
  • composition can also optionally comprise a high molecular weight silicone surfactant that can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • a high molecular weight silicone surfactant that can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • the silicone surfactant may be a high molecular weight polymer of dimethyl polysiloxane with polyoxethylene and/or polyoxpropylene side chains having a molecular weight of from 10,000 to 50,000.
  • the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane.
  • the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
  • volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).
  • a preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING.
  • the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
  • adjuncts examples include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humectants, such as glycerol, ethoxylated glycerins such as glycereth-26, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe Vera, cornflower, witch hazel, elderflower, cucumber; as well as acerola cherry fermentate, thickeners; activity enhancers; colorants; and perfumes.
  • Cosmetic adjuncts can form the balance of the composition.
  • anti-inflammatory and/or anti-irritant agents may also be desirable to incorporate anti-inflammatory and/or anti-irritant agents.
  • the natural anti-inflammatory and/or anti-irritant agents are preferred.
  • licorice and its extracts, dipotassium glycyrrhizinate, oat and oat extracts, candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia cordifolial), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), may be used.
  • Skin conditioning agents such hyaluronic acid, its derivatives and salts including sodium hyaluronate, plant extracts such as kola nut, guarana mate, algae extract and skin benefit agents such as ceramides, glycoceramides, pseudoceramides, sphingolipids such as sphingomyelins, cerebrosides, sulphatides, and ganglioside, sphingosines, dihydrosphingosine, phytosphingosines, phospholipids, may also be incorporated, either separately or in mixtures. Fatty acids may also be combined with these skin benefit agents.
  • the ceramides and glycoceramides include those described in U.S. Patent No.
  • the pseudoceramides include those described in U.S. Patent No. 5,198,210; 5,206,020; and 5,415,855, the relevant disclosures of which are incorporated herein by reference.
  • Example 1 illustrate, but do not limit, the present invention. Unless otherwise indicated, all parts and percentages are by weight. Example 1
  • the following is a topical skin composition according to the present invention.
  • Example 2 The following is a topical skin composition according to one embodiment of the present invention.
  • the composition provides a defense against ROS and also includes ingredients to help repair damage caused ROS.
  • Example 3 The following is a topical skin composition according to one embodiment of the present invention.
  • the composition provides a defense against ROS and also includes ingredients to help repair damage caused ROS.
  • EXAMPLE 4 The following tests were performed to determine the effect of providing a complex composition according to the present invention in comparison to a placebo, Vitamin E, and Vitamin C. The tests were conducted by outlining a number of two inch sections on the back of a human. The following formulas were applied in a randomized manner to the sections.
  • FIGs. 1 and 2 show the results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition topique pour la peau renfermant un complexe contenant une quantité efficace de composés sélectionnés destinés à assurer une défense contre les divers mécanismes de cheminement des espèces réactives de l'oxygène. Ladite composition vise à prévenir les effets adverses ou préjudiciables de ces espèces réactives de l'oxygène. La figure illustre d'ailleurs les résultats en termes d'érythème cutané d'un sujet exposé à des rayons ultraviolets après application de la formulation de l'exemple 4.
EP00980601A 1999-11-24 2000-11-21 Composition topique pour la peau Withdrawn EP1231886A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16753999P 1999-11-24 1999-11-24
US167539P 1999-11-24
PCT/US2000/031933 WO2001037788A1 (fr) 1999-11-24 2000-11-21 Composition topique pour la peau

Publications (2)

Publication Number Publication Date
EP1231886A1 true EP1231886A1 (fr) 2002-08-21
EP1231886A4 EP1231886A4 (fr) 2005-10-12

Family

ID=22607783

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00980601A Withdrawn EP1231886A4 (fr) 1999-11-24 2000-11-21 Composition topique pour la peau

Country Status (6)

Country Link
EP (1) EP1231886A4 (fr)
KR (1) KR20030016202A (fr)
CN (1) CN1424900A (fr)
AU (1) AU1784301A (fr)
HK (1) HK1050840A1 (fr)
WO (1) WO2001037788A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003536A1 (en) * 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
DE10111053A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Wirkstoffkombinationen aus alpha-Liponsäure und Biochinonen
DE10111046A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen,zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
EP1474158B1 (fr) 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prévention et traitement des troubles liés au stress oxydatif à l'aide de composés élevant le taux intracellulaire de glutathione ou d'enzymes de detoxification de phase ii
DE10257949A1 (de) * 2002-12-12 2004-07-01 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Thiodiglycol
TWI322008B (en) 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
PL1591105T3 (pl) 2004-03-17 2020-11-30 Stada Arzneimittel Ag Zastosowanie przeciwutleniaczy do wytwarzania kompozycji farmaceutycznej lub kosmetycznej do ochrony skóry przed uszkodzeniem wywołanym przez promieniowanie podczerwone
KR100883757B1 (ko) * 2007-03-12 2009-02-12 성균관대학교산학협력단 신경전달물질 배출을 조절하기 위한 폴리페놀 화합물
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
CN103394088B (zh) 2008-01-25 2017-01-18 Msd 消费保健品公司 选择用于局部施用组合物的抗氧化剂的方法
JP5796881B2 (ja) * 2008-02-07 2015-10-21 マーケット ユニバーシティー 統合失調症を治療するため及び薬物渇望を低減するためのシステイン及びシスチンプロドラッグ
WO2011081716A1 (fr) * 2009-12-28 2011-07-07 N.V. Perricone Llc Formulations topiques à base d'acylglutathion
US8580742B2 (en) 2010-03-05 2013-11-12 N.V. Perricone Llc Topical glutathione formulations for menopausal skin
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
US8609604B2 (en) 2009-12-28 2013-12-17 N.V. Perricone Llc Methods of improving the appearance of aging skin
US8609618B2 (en) * 2011-03-25 2013-12-17 N.V. Perricone Llc Topical palmitoyl glutathione formulations
TWI549696B (zh) * 2014-09-05 2016-09-21 中國醫藥大學 麥角硫因應用於活化細胞之Ｎｒｆ２訊息途徑之用途
US10063312B2 (en) * 2016-06-21 2018-08-28 Futurewei Technologies, Inc. Optical network unit reset message
US20230157939A1 (en) * 2020-04-28 2023-05-25 Conopco, Inc., D/B/A Unilever Personal care compositions with enhanced solubility actives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
WO1999000106A1 (fr) * 1997-06-27 1999-01-07 Thione International, Inc. Preparations intra-orales antioxydantes
US5866142A (en) * 1995-07-20 1999-02-02 Riordan; Neil H. Skin treatment system
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
WO2001026617A1 (fr) * 1999-10-08 2001-04-19 Coty B.V. Preparation cosmetique a base de principes actifs presentant un facteur de protection anti-radicaux libres synergiquement eleve

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5935596A (en) * 1997-03-20 1999-08-10 Chesebrough-Pond's Usa Co. Delivery of skin benefit agents via adhesive strips

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5866142A (en) * 1995-07-20 1999-02-02 Riordan; Neil H. Skin treatment system
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US5840681A (en) * 1996-05-31 1998-11-24 Thione International, Inc. X-ray induced skin damage protective composition
WO1999000106A1 (fr) * 1997-06-27 1999-01-07 Thione International, Inc. Preparations intra-orales antioxydantes
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
WO2001026617A1 (fr) * 1999-10-08 2001-04-19 Coty B.V. Preparation cosmetique a base de principes actifs presentant un facteur de protection anti-radicaux libres synergiquement eleve

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MONTENEGRO, L. ET AL: "Protective effect evaluation of free radical scavengers on UVB induced human cutaneous erythema by skin reflectance spectrophotometry" INTERNATIONAL JOURNAL OF COSMETIC SCIENCE , 17(3), 91-103 CODEN: IJCMDW; ISSN: 0142-5463, 1995, XP009052473 *
See also references of WO0137788A1 *

Also Published As

Publication number Publication date
EP1231886A4 (fr) 2005-10-12
CN1424900A (zh) 2003-06-18
HK1050840A1 (zh) 2003-07-11
WO2001037788A1 (fr) 2001-05-31
KR20030016202A (ko) 2003-02-26
AU1784301A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
US20030095959A1 (en) Topical skin composition
US20080081034A1 (en) Topical Skin Compositions, Their Preparation, and Their Use
US20080124409A1 (en) Topical Skin Compositions, Their Preparation, and Their Use
WO2001037788A1 (fr) Composition topique pour la peau
CA2907495C (fr) Compositions d'antioxydants et procedes d'utilisation
EP1002526B1 (fr) Composition pour le blanchiment de la peau contenant un extrait de busserole et un réducteur
EP0799023B1 (fr) Utilisation de flavono des comme agents immunomodulateurs ou immunoprotecteurs dans des preparations cosmetiques ou dermatologiques
EP2736484B1 (fr) Compositions végétales antioxydantes
JP2731705B2 (ja) 化粧料組成物及び皮膚科用医薬組成物
JP2774926B2 (ja) 皮膚保護用組成物
JPH09510724A (ja) 皮膚の老化に対して活性な、物質類又は活性化合物組み合わせ物類及び調製物類
EP0514067A1 (fr) Composition cosmétique
JP2008513378A (ja) リン酸化ポリフェノールを含有する局所組成物
JPH11513384A (ja) 老化皮膚に対する皮膚手入れ用薬剤
US20060210515A1 (en) Hair growth formula
AU2002360571B2 (en) Methods for improving the aesthetic appearance of skin
KR950007045B1 (ko) 폴리에톡실레이티드 비타민 e를 함유한 피부화장료
JPH08268859A (ja) シワ予防・改善化粧料
JP4889069B2 (ja) 保湿剤、美白剤および皮膚化粧料
JP2005104938A (ja) 皮膚用化粧料
WO2003075880A1 (fr) Compositions cosmetiques renfermant des triesters d'acide citrique
JPH08231366A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ACCESS BUSINESS GROUP INTERNATIONAL LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20050826

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/355 B

Ipc: 7A 61K 31/34 B

Ipc: 7A 61K 7/48 B

Ipc: 7A 61K 31/16 B

Ipc: 7A 61K 31/135 B

Ipc: 7A 61K 7/42 B

Ipc: 7A 61K 47/00 B

Ipc: 7A 61K 39/385 B

Ipc: 7A 61K 35/78 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061130

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1050840

Country of ref document: HK